Evaluating Medline (MDLN) Valuation After Recent Fundamentals And Share Price Weakness

Simply Wall St.03-04

AdvertisementWhat Medline’s recent fundamentals mean for investors Medline (MDLN) has drawn fresh attention after investors focused on its latest reported fundamentals, including US$28.4b in revenue, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616539226?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","is_english":true,"pubTime":"2026-03-04 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616539226","market":"nz","top_or_hot":-1,"title":"Evaluating Medline (MDLN) Valuation After Recent Fundamentals And Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat Medline’s recent fundamentals mean for investors Medline (MDLN) has drawn fresh attention after investors focused on its latest reported fundamentals, including US$28.4b in revenue, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-mdln/medline/news/evaluating-medline-mdln-valuation-after-recent-fundamentals\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evaluating Medline (MDLN) Valuation After Recent Fundamentals And Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvaluating Medline (MDLN) Valuation After Recent Fundamentals And Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-04 18:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-mdln/medline/news/evaluating-medline-mdln-valuation-after-recent-fundamentals><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat Medline’s recent fundamentals mean for investors Medline (MDLN) has drawn fresh attention after investors focused on its latest reported fundamentals, including US$28.4b in revenue, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-mdln/medline/news/evaluating-medline-mdln-valuation-after-recent-fundamentals\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDLN","symbol_name":"Medline Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-mdln/medline/news/evaluating-medline-mdln-valuation-after-recent-fundamentals","article_id":"2616539226","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-mdln/medline/news/evaluating-medline-mdln-valuation-after-recent-fundamentals","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616539226","pubTimestamp":1772620411,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What Medline’s recent fundamentals mean for investors\nMedline (MDLN) has drawn fresh attention after investors focused on its latest reported fundamentals, including US$28.4b in revenue, US$1.2b in net income, and single digit annual growth rates across both measures.\nSee our latest analysis for Medline.\nDespite US$28.4b of revenue and US$1.2b of net income drawing focus to fundamentals, Medline’s recent 1-day share price return of a 3.18% decline and 7-day share price return of an 11.2%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDLN":"Medline Inc","BK4198":"医疗保健用品","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"在近期基本面和股价疲软后评估Medline(MDLN)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDLN":1.5,"DCF":1},"content_text":"AdvertisementWhat Medline’s recent fundamentals mean for investors Medline (MDLN) has drawn fresh attention after investors focused on its latest reported fundamentals, including US$28.4b in revenue, US$1.2b in net income, and single digit annual growth rates across both measures. See our latest analysis for Medline. Despite US$28.4b of revenue and US$1.2b of net income drawing focus to fundamentals, Medline’s recent 1-day share price return of a 3.18% decline and 7-day share price return of an 11.2% decline contrast with a 9.28% year-to-date share price return. This suggests earlier momentum has softened near the current US$44.39 level. If this has you thinking about where else capital could work harder, it may be worth scanning our 31 healthcare AI stocks as a starting point for other health focused opportunities. With Medline trading at US$44.39 alongside single digit revenue growth, faster net income growth and a discount to both analyst and intrinsic estimates, investors may wonder whether this represents a buying opportunity or whether future growth is already priced in. Preferred P/E of 31.1x: Is it justified? On our data, Medline trades on a P/E of 31.1x at the last close of $44.39, which screens as expensive versus both its industry and peer group. The P/E multiple compares the current share price to earnings per share, so a higher figure often reflects the market paying up for current or expected earnings. For a med-surg and supply chain operator like Medline, this multiple is one way for investors to weigh its earnings profile against other Medical Equipment names. Here, the company is described as trading at a 10.7% discount to our SWS DCF model estimate of $49.71. However, it is still on a P/E that is above both the US Medical Equipment industry average of 30.9x and a peer average of 29.4x. That combination suggests the market is assigning a relatively full earnings multiple while our DCF work points to some gap between price and estimated cash flow value. Relative to peers, the signals are consistent. Medline is marked as expensive based on its 31.1x P/E compared with the 30.9x industry average and 29.4x peer average, so investors are effectively paying a premium earnings multiple versus comparable companies. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-earnings of 31.1x (OVERVALUED) However, you still need to weigh risks such as execution missteps in supply chain services or pressure on margins across Medline’s broad med surg product range. Find out about the key risks to this Medline narrative. Another view based on our DCF work While the 31.1x P/E screens as expensive, our SWS DCF model suggests an estimated fair value of $49.71 per share. At the current $44.39 price, that is a 10.7% discount, which leads to a different perspective on valuation risk and opportunity. Which signal do you trust more? Look into how the SWS DCF model arrives at its fair value. MDLN Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Medline for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of signals feels finely balanced, it is worth checking the details for yourself and forming a clear view while sentiment is still shifting. Then weigh up the 3 key rewards and 1 important warning sign to see how that balance of risks and rewards lines up with your own thesis. Looking for more investment ideas? You have seen how one company stacks up, but your next step is to compare it with a wider set of ideas that match your goals and risk comfort.  Target resilience first by checking companies that pass our 75 resilient stocks with low risk scores so you can focus on ideas with fewer red flags. Hunt for potential bargains using our 49 high quality undervalued stocks and see which names currently screen as priced below their assessed quality. Zero in on financial strength with the solid balance sheet and fundamentals stocks screener (40 results) to find businesses that pair fundamentals with balance sheets that look more robust.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616539226","isCrawlerRequest":true}